Treatment of residual disease following neoadjuvant therapy in breast cancer
Journal of Surgical Oncology · 2024-01 · 129 (1) · 18-25
DOI: 10.1002/jso.27523 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, online erschienen am 22.11.2023. Verfasst von Natalie K Heater und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Substantial advances have been made in the systemic treatment of breast cancer with residual disease following neoadjuvant therapy. We reviewed recent and ongoing studies informing the standard clinical management of residual disease by subtype: HER2+, TNBC, and HR+/HER2‐, as well as strategies for BRCA+ disease. We conclude with a discussion of ongoing clinical trials and current controversies regarding the treatment of residual disease in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA.
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Zitieren
APA
Heater, N. K., Somayaji, K., & Gradishar, W. (2024). Treatment of residual disease following neoadjuvant therapy in breast cancer. Journal of Surgical Oncology, 129(1), 18-25. https://doi.org/10.1002/jso.27523
Vancouver
Heater NK, Somayaji K, Gradishar W. Treatment of residual disease following neoadjuvant therapy in breast cancer. Journal of Surgical Oncology. 2024;129(1):18-25. doi:10.1002/jso.27523
BibTeX
@article{Heater2024,
author = {Heater, Natalie K and Somayaji, Khyati and Gradishar, William},
title = {Treatment of residual disease following neoadjuvant therapy in breast cancer},
journal = {Journal of Surgical Oncology},
year = {2024},
volume = {129},
number = {1},
pages = {18--25},
doi = {10.1002/jso.27523}
}
EUVIMED